Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05072249
Other study ID # MR903 9501
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 8, 2021
Est. completion date December 30, 2023

Study information

Verified date March 2023
Source King's College London
Contact Dr Metrebian
Phone 07957757235
Email nicola.metrebian@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to assess the effectiveness of take-home naloxone (THN) to reverse opioid overdose when administered by lay persons in a real world setting. This multicentre, prospective, observational cohort study will be conducted across Europe using a mixed method approach. Recruiting 6000 individuals to whom a supply of THN has been provided, for n=600 to witness an opioid overdose. The co-primary outcomes are to determine the rate of administration of naloxone and frequency of deaths in the 24 hours subsequent to the administration of naloxone. This will be captured through structured interviews with those who report witnessing an opioid overdose in the 6 month study period, approximately n=600, to elicit further information on the overdose and any naloxone administered. Naloxone training materials and education provided will be examined through questions in the structured interview. In-depth qualitative interviews will also be conducted with 60 participants who have witnessed an overdose, in order to better understand the use, safety and effectiveness of different naloxone products (particularly Nyxoid). As part of the qualitative analysis, interview transcripts will be assessed by an expert clinician panel for accuracy of diagnosis, actions taken and aftercare. Routine data from national health registers will be used to gather mortality data. This study will report on the use of different formulations of naloxone. In addition, this study serves as a Post Authorisation Efficacy Study (PAES) for the intranasal (IN) naloxone, Nyxoid developed by MundiPharma and focuses on drug safety and training.


Description:

Accidental opioid overdose is a global crisis. Naloxone is an accessible, safe and effective antidote for this preventable cause of mortality. While it has been used to treat opioid overdose in hospital and pre-hospital settings since the 1970s, take home naloxone programmes have been introduced more recently after opioid users were recognised as potential first responders. This study aims to assess the effectiveness of take-home naloxone (THN) to reverse opioid overdose when administered by lay persons in a real world setting. This multicentre, prospective, observational cohort study will be conducted across Europe using a mixed method approach, recruiting 6000 individuals to whom a supply of THN has been provided (comprising four groups:1. patients in treatment for opioid use disorder (OUD), 2. Individuals using opioids but out-of-treatment, 3. family members, friends and other close carers, and 4. staff working with individuals with OUD) for n=600 to witness an opioid overdose. The co-primary outcomes are to determine the rate of administration of naloxone and frequency of deaths in the 24 hours subsequent to the administration of naloxone. This will be captured through two stages and two sub-studies. Main study stage 1: All consenting participants (n=6,000) will be asked to complete an enrolment questionnaire with the member of staff recruiting them into the study. In addition, the staff member will be asked to complete a brief record of the naloxone and training provided to the participant. Participants will be texted monthly to prompt them to contact research staff if they have witnessed an opioid overdose. Staff who have frequent or regular contact with participants (including instances when a replenishment of naloxone is given) will also prompt participants to make contact with research staff to notify them of a witnessed opioid overdose. All participants will be contacted at six months and asked to take part in a structured interview. In addition, national/regional death registers will be probed to confirm mortality data for study participants who are at risk of experiencing an opioid overdose themselves. Main study, Stage 2: Participants who report that they have witnessed an opioid overdose during the six-month follow-up period will be asked to take part in a structured interview with a researcher about this witnessed overdose to capture our primary outcomes (approximately n=600). Sub-study A: comprises two structured surveys incorporated into a) the Enrolment training information form (to examine naloxone training and materials provided) and b) the Stage 2 Interview completed by participants who have witnessed an overdose (to ask about the extent they followed the nasal naloxone Nyxoid Quick Start Guide (QSG) (or equivalent instructions). The questions are designed to better understand the effectiveness of the Nyxoid nasal naloxone educational and training materials delivered to participants who were provided with Nyxoid nasal naloxone and who were subsequently present at an overdose. Sub-study B: comprises qualitative interviews with 60 UK participants who witness a diverse range of overdose events of the approx. n=600 (Main Study Stage 2). The aim of sub-study B is to better understand the use, safety, and effectiveness of different naloxone products. Qualitative interviews will be guided by a topic guide and conducted by telephone. The topic guide will capture details of any overdoses experienced or witnessed since the study started before focusing in more depth on the most recent overdose witnessed. Participants will also be asked about any training they have had, or need, in naloxone administration. In addition, a clinical expert assessment of the accurate identification of an opioid overdose and the participant's response to the opioid overdose (as detailed in the transcribed interviews) will be performed and documented. Answers will be assessed by an expert clinician panel for accuracy of diagnosis, actions taken and aftercare. This study will report on the use of different formulations of naloxone, and different national systems of training and provision. In addition, this study serves as a Post Authorisation Efficacy Study (PAES) for the intranasal (IN) naloxone, Nyxoid developed by Mundipharma and focuses on drug safety and training.


Recruitment information / eligibility

Status Recruiting
Enrollment 6000
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Member of at least one of the groups above (a-d) - Aged =18 years - Provided with THN supply at time of enrolment (or can demonstrate that they have a supply of THN (in-date) and have received training at time of enrolment). - Have access to reliable mobile telephone and can present it. - Willing to participate in follow-up - Who have provided written informed consent. Exclusion Criteria: The following persons will be excluded: - Needs an interpreter - Already entered the study - Not willing or able to partake in follow-up telephone survey

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Naloxone
Take Home Naloxone for reversing opioid overdose

Locations

Country Name City State
Denmark SundhedsTeam, Socialforvaltningen, Københavns Kommune Copenhagen
Sweden Stockholm Centre for Dependency Disorders Stockholm
United Kingdom Birmingham and Solihull Mental Health Foundation Trust Birmingham
United Kingdom Public Health Wales Cardiff
United Kingdom Scottish Drugs Forum Glasgow
United Kingdom South London and the Maudsley London

Sponsors (2)

Lead Sponsor Collaborator
King's College London Mundipharma Research Limited

Countries where clinical trial is conducted

Denmark,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of participants that received various forms of Nyxoid training materials during their naloxone training (patient information card, training video, information on leaflet and images in nyxoid pack). Percentage (n=3000 (only those receiving nyxoid)) Enrolment & Stage 1 interview conducted at 6 months
Other Percentage of participants (receiving nyxoid) that appropriately recognised and responded to an overdose. Percentage (n=300 (only those receiving nyxoid witnessing O/D) Ongoing interviews 6-months post enrolment follow-up
Other Percentage of participants (receiving nyxoid) that appropriately responded to an overdose. percentage (n=300) Ongoing interviews 6-months post enrolment follow-up
Other Percentage of participants that had received nyxoid naloxone training prior to enrolling Percentage (n=3000) Enrolment
Other Positive response given (by those receiving nyxoid) stating no improvement after 2-3 minutes OR overdose symptoms come back Percentage (n=300) Ongoing interviews 6-months post enrolment follow-up
Other Percentage of participants (receiving nyxoid) that inappropriately responded to an overdose. Percentage (n=300) Ongoing interviews 6-months post enrolment follow-up
Other Increased understanding of carriage of naloxone products and disposal of used kits Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of how naloxone is administered in an emergency overdose situation, including any problems encountered (e.g. device malfunction or misuse) Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of decision making processes relating to naloxone administration in an emergency opioid overdose situation, including giving/not giving a second dose Qualitative interview with those having witnessed an opioid overdose from UK 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of the impact of the social and environmental setting in which the overdose occurs - on naloxone use n=60 qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of the links between naloxone carriage and use on willingness to call an ambulance when witnessing an opioid overdose Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of the effectiveness of naloxone administration, including speed of reversal and opioid overdose outcome Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of any negative consequences of naloxone administration (e.g. victim withdrawals, aggression, respiratory depression and death) and their implications for future opioid overdose events witnessed Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of care of the victim both during the opioid overdose and post-naloxone administration Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of knowledge of naloxone, including training and information needs Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Increased understanding of views on the THN training materials Qualitative interview with those having witnessed an opioid overdose from UK n=60 6-month follow-up (at most recent overdose witnessed)
Other Accurate diagnosis of Opioid overdose. Expert assessment of transcripts of qualitative interviews using non-validated naloxone administration scale. 5-point Likert scale (1 (very low)- 5 (very high) 6-month follow-up (at most recent overdose witnessed)
Other Accurate identification of respiratory depression. Expert assessment of transcripts of qualitative interviews using non-validated naloxone administration scale. 5-point Likert scale (1 (very low)- 5 (very high). 6-month follow-up (at most recent overdose witnessed)
Other Appropriate response to opioid overdose Expert assessment of transcripts of qualitative interviews using non-validated naloxone administration scale. 5-point Likert scale (1 (very low)- 5 (very high) 6-month follow-up (at most recent overdose witnessed)
Other Adequate post naloxone aftercare. Expert assessment of transcripts of qualitative interviews using non-validated naloxone administration scale. 5-point Likert scale (1 (very low)- 5 (very high) 6-month follow-up (at most recent overdose witnessed)
Primary Frequency of deaths in the 24 hours or later if information is available subsequent to administration of naloxone by lay-persons to reverse an opioid overdose in the real world. frequency of deaths among those witnessing opioid overdose (n=600) Ongoing - over six months period post enrolment (at most recent overdose witnessed)
Primary Administration rate of THN with the intention of reversing an opioid overdose by lay persons provided with THN who witness an opioid overdose. Rate of THN administration among those witnessing opioid overdose (n=600) Ongoing -over six months period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants who indicate carrying THN (on day of interview) Percentage (n=6000) Ongoing over 6-month period post enrolment
Secondary Percentage of participants who witness an opioid overdose over 6-month period. Percentage (n=6000) Ongoing over 6-month period post enrolment
Secondary Confirm death or survival of participants percentage (n=600) On-going over 6 month period post enrolment
Secondary Percentage of participants who witness an opioid overdose who report there was THN present Percentage (n=600) Ongoing over 6-month period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants who are carrying THN when witness an opioid overdose Percentage (n=600) Ongoing over 6-month period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants who witness an opioid overdose, where there was THN present, and administer THN Percentage (n=600) Ongoing over 6-month period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants who witness an overdose and administer THN who report respiratory depression occurred in person they resuscitated within one hour of administering THN Percentage (n=600) On-going within 6-month period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants who witness an overdose, who report a second dose of naloxone administered to a person experiencing an opioid overdose within 1-hour post administration of first dose of THN Percentage (n=600) 6-month follow-up (at most recent overdose witnessed)
Secondary Percentage of participants who report withdrawal symptoms (including anger, rage and violence) occurred in person they resuscitated with THN Frequency of each symptom witnessed (n=600) (at most recent overdose witnessed) On-going over 6-month period post enrolment (at most recent overdose witnessed)
Secondary Percentage of participants witnessing an overdose where the person receiving naloxone has survived at 2 hours post administration of naloxone OR at arrival of ambulance/medical assistance if this occurs before 2 hours have passed since opioid overdose Percentage (n=600) Ongoing over 6-month period post enrolment
Secondary Percentage of participants who witness an opioid overdose and report fatal outcomes within 2 hours of identification of opioid overdose or at arrival of ambulance/medical assistance a) of witnessed opioid overdoses b) Of witnessed opioid overdoses Percentage (n=600) Ongoing over 6-month period post enrolment
Secondary Percentage of participants who witness an overdose who correctly diagnosed opioid overdose crisis-through multiple response questions Percentage (n=600) Ongoing interviews 6-month post enrolment follow-up
Secondary Percentage of participants who witness an opioid overdose who correctly diagnose opioid overdose crisis-through multiple response questions Percentage (n=600) Ongoing interviews 6-month post enrolment follow-up
Secondary Percentage of participants who witness an opioid overdose who correctly respond to opioid overdose crisis-through multiple response questions Percentage (n=600) Ongoing interviews 6-month post enrolment follow-up
See also
  Status Clinical Trial Phase
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Recruiting NCT03924505 - Preventing Opioid Overdose Mortality in the United States N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Completed NCT05219669 - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Phase 1
Completed NCT04317053 - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program Phase 3
Not yet recruiting NCT06466005 - UnityPhilly Response App for Overdose Reversal
Recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Suspended NCT05114460 - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal Phase 2
Recruiting NCT06238128 - Opioid Rapid Response System: Naloxone Training in Communities N/A
Completed NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting NCT05944133 - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed NCT05377255 - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults Phase 1
Recruiting NCT05877118 - Improving Availability of Intranasal Naloxone N/A
Withdrawn NCT05808881 - Clinical Outcomes From Nalmefene Phase 4
Not yet recruiting NCT01622504 - Naloxone Nasal Spray Pharmacokinetic Study Phase 1
Not yet recruiting NCT06429436 - Vending Machine Naloxone Distribution for Your Community (VENDY) Phase 4
Completed NCT05506267 - Development of a Tracheal Sound Sensor
Completed NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Not yet recruiting NCT06408714 - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Phase 3